Treat hypercalcemia of malignancy with IV bisphosphonate or denosumab
STEP 1 — Gather Information
Confirm adult patient with malignancy-associated hypercalcemia: symptoms (fatigue, nausea, polyuria, etc.), serum calcium above upper limit of normal, underlying malignancy documented. Collect serum calcium (adjusted for albumin or ionized calcium), renal function (eGFR), malignancy type, and prior antiresorptive exposure.
STEP 2 — Rule In / Rule Out
If hypercalcemia is attributable to malignancy (HCM) and not to primary hyperparathyroidism, vitamin D excess, or other non‑malignant causes, proceed to treatment; otherwise, pursue alternative diagnosis and do not initiate antiresorptive therapy for HCM.
STEP 3 — Classify or Stratify
Assess renal function to guide agent selection: if eGFR <30 mL/min/1.73 m², prefer denosumab; if eGFR ≥30 mL/min/1.73 m², either intravenous bisphosphonate (pamidronate or zoledronic acid) or denosumab may be used.
STEP 4 — Decide
Administer intravenous bisphosphonate (pamidronate 60–90 mg IV over 2–24 hours or zoledronic acid 4 mg IV over 15 minutes) or denosumab 120 mg subcutaneously, based on renal function and drug availability.
Clinical Guardrails / Mimics / Pitfalls
Do not use in patients without malignancy‑associated hypercalcemia; avoid in severe uncorrected hypocalcemia; monitor serum calcium and renal function after infusion; avoid rapid calcium correction that may precipitate arrhythmias; do not rely solely on antiresorptives in severe HCM without considering adjunct calcitonin for immediate calcium reduction; avoid in patients with known hypersensitivity to bisphosphonates or denosumab.
Concrete Clinical Example
A 62‑year‑old woman with metastatic breast cancer presents with fatigue and nausea; serum calcium 13.8 mg/dL (albumin 4.0 g/dL). Malignancy confirmed, eGFR 45 mL/min/1.73 m², no prior bisphosphonate. Initiate zoledronic acid 4 mg IV over 15 minutes.
Source: Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2023, DOI: 10.1210/clinem/dgac621